A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neovascularisation, a major risk factor of corneal graft rejection.

Trial Profile

A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neovascularisation, a major risk factor of corneal graft rejection.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Aganirsen (Primary)
  • Indications Corneal disorders
  • Focus Therapeutic Use
  • Sponsors Laboratoires CTRS
  • Most Recent Events

    • 24 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top